title: Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier.
abstract: Transport of L-[3H]carnitine and acetyl-L-[3H]carnitine at the blood-brain barrier (BBB) was examined by using in vivo and in vitro models. In vivo brain uptake of acetyl-L-[3H]carnitine, determined by a rat brain perfusion technique, was decreased in the presence of unlabeled acetyl-L-carnitine and in the absence of sodium ions. Similar transport properties for L-[3H]carnitine and/or acetyl-L-[3H]carnitine were observed in primary cultured brain capillary endothelial cells (BCECs) of rat, mouse, human, porcine and bovine, and immortalized rat BCECs, RBEC1. Uptakes of L-[3H]carnitine and acetyl-L-[3H]carnitine by RBEC1 were sodium ion-dependent, saturable with K(m) values of 33.1 +/- 11.4 microM and 31.3 +/- 11.6 microM, respectively, and inhibited by carnitine analogs. These transport properties are consistent with those of carnitine transport by OCTN2. OCTN2 was confirmed to be expressed in rat and human BCECs by an RT-PCR method. Furthermore, the uptake of acetyl-L-[3H]carnitine by the BCECs of juvenile visceral steatosis (jvs) mouse, in which OCTN2 is functionally defective owing to a genetical missense mutation of one amino acid residue, was reduced. The brain distributions of L-[3H]carnitine and acetyl-L-[3H]carnitine in jvs mice were slightly lower than those of wild-type mice at 4 h after intravenous administration. These results suggest that OCTN2 is involved in transport of L-carnitine and acetyl-L-carnitine from the circulating blood to the brain across the BBB.
authors.affiliation: Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kido
authors.forename: I
authors.initials: I
authors.lastname: Tamai
authors.forename: A
authors.initials: A
authors.lastname: Ohnari
authors.forename: Y
authors.initials: Y
authors.lastname: Sai
authors.forename: T
authors.initials: T
authors.lastname: Kagami
authors.forename: J
authors.initials: J
authors.lastname: Nezu
authors.forename: H
authors.initials: H
authors.lastname: Nikaido
authors.forename: N
authors.initials: N
authors.lastname: Hashimoto
authors.forename: M
authors.initials: M
authors.lastname: Asano
authors.forename: A
authors.initials: A
authors.lastname: Tsuji
mesh_terms: D000108:Acetylcarnitine / Q000493:pharmacokinetics*; D000818:Animals; D001812:Blood-Brain Barrier / Q000502:physiology*; D001921:Brain / Q000378:metabolism*; D001923:Brain Chemistry / Q000502:physiology*; D002196:Capillaries / Q000187:drug effects / Q000378:metabolism; D002331:Carnitine / Q000493:pharmacokinetics*; D002352:Carrier Proteins / Q000378:metabolism*; D002478:Cells, Cultured; D002560:Cerebrovascular Circulation / Q000187:drug effects; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D051379:Mice; D008809:Mice, Inbred C3H; D027701:Organic Cation Transport Proteins; D051381:Rats; D017208:Rats, Wistar; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000074058:Solute Carrier Family 22 Member 5; D014018:Tissue Distribution
chemical_list: D002352:Carrier Proteins; D008565:Membrane Proteins; D027701:Organic Cation Transport Proteins; C492020:SLC22A5 protein, human; D000074058:Solute Carrier Family 22 Member 5; D000108:Acetylcarnitine; D002331:Carnitine